Intratumoral neoadjuvant immunotherapy using IL-12 and dendritic cells is an effective strategy to control recurrence of murine hepatocellular carcinoma in immunosuppressed mice

Journal of Immunology

Volumn 185, Issue 1, 2010, Pages 698-708

  Kayashima, Hiroto ^a   Toshima, Takeo ^a   Okano, Shinji ^a   Taketomi, Akinobu ^a   Harada, Noboru ^a   Yamashita, Yo Ichi ^a   Tomita, Yukihiro ^a   Shirabe, Ken ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENCY; FEMALE; GENE; HOST; IL 12 GENE; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TRANSPLANTATION; LUNG METASTASIS; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SKIN GRAFT; T LYMPHOCYTE; ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; C3H MOUSE; GENE THERAPY; GENETICS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INTRALESIONAL DRUG ADMINISTRATION; LIVER TUMOR; METHODOLOGY; PATHOLOGY; TRANSPLANTATION; TUMOR CELL LINE; TUMOR RECURRENCE;

ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; GENE THERAPY; IMMUNOSUPPRESSION; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRALESIONAL; INTERLEUKIN-12; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL;

EID: 77956211778     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900187     Document Type: Article

References (71)

1. Waldmann, T. A. 2003. Immunotherapy: past, present and future. Nat. Med. 9: 269-277.
2. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
3. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
4. Kim, R., M. Emi, K. Tanabe, and K. Arihiro. 2006. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 66: 5527-5536. (Pubitemid 43927099)
5. Gabrilovich, D. 2004. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4: 941-952.
6. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6: 295-307.
7. Nagaraj, S., K. Gupta, V. Pisarev, L. Kinarsky, S. Sherman, L. Kang, D. L. Herber, J. Schneck, and D. I. Gabrilovich. 2007. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13: 828-835.
8. Hamzah, J., M. Jugold, F. Kiessling, P. Rigby, M. Manzur, H. H. Marti, T. Rabie, S. Kaden, H. J. Gröne, G. J. Hämmerling, et al. 2008. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453: 410-414.
9. Parkin, D. M., F. Bray, J. Ferlay, and P. Pisani. 2005. Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74-108.
10. Mazzaferro, V., E. Regalia, R. Doci, S. Andreola, A. Pulvirenti, F. Bozzetti, F. Montalto, M. Ammatuna, A. Morabito, and L. Gennari. 1996. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334: 693-699.
11. Eguchi, S., M. Takatsuki, M. Hidaka, Y. Tajima, and T. Kanematsu. 2008. Evolution of living donor liver transplantation over 10 years: experience of a single center. Surg. Today 38: 795-800.
12. Roayaie, S., J. S. Frischer, S. H. Emre, T. M. Fishbein, P. A. Sheiner, M. Sung, C. M. Miller, and M. E. Schwartz. 2002. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann. Surg. 235: 533-539.
13. Todo, S., H. Furukawa, and Japanese Study Group on Organ Transplantation. 2004. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann. Surg. 240: 451-459, discussion 459-461.
14. Ceriello, A., F. Mezza, S. Cozzolino, G. Pettinato, A. Mancini, W. Santaniello, F. Calise, and O. Cuomo. 1994. Role of immunosuppression in recurrence after liver transplantation for diethylnitrosamine-induced tumors in rats. Transpl. Int. 7(Suppl 1): S204-S207.
15. Yokoyama, I., B. Carr, H. Saitsu, S. Iwatsuki, and T. E. Starzl. 1991. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 68: 2095-2100.
16. Colombo, M. P., and G. Trinchieri. 2002. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13: 155-168.
17. Voest, E. E., B. M. Kenyon, M. S. O'Reilly, G. Truitt, R. J. D'Amato, and J. Folkman. 1995. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87: 581-586.
18. Del Vecchio, M., E. Bajetta, S. Canova, M. T. Lotze, A. Wesa, G. Parmiani, and A. Anichini. 2007. Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 13: 4677-4685.
19. Harada, N., M. Shimada, S. Okano, T. Suehiro, Y. Soejima, Y. Tomita, and Y. Maehara. 2004. IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. J. Immunol. 173: 6635-6644.
20. Klebanoff, C. A., L. Gattinoni, and N. P. Restifo. 2006. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211: 214-224.
21. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
22. Candido, K. A., K. Shimizu, J. C. McLaughlin, R. Kunkel, J. A. Fuller, B. G. Redman, E. K. Thomas, B. J. Nickoloff, and J. J. Mulé. 2001. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res. 61: 228-236.
23. Shibata, S., S. Okano, Y. Yonemitsu, M. Onimaru, S. Sata, H. Nagata-Takeshita, M. Inoue, T. Zhu, M. Hasegawa, Y. Moroi, et al. 2006. Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene. J. Immunol. 177: 3564-3576.
24. Pflanz, S., J. C. Timans, J. Cheung, R. Rosales, H. Kanzler, J. Gilbert, L. Hibbert, T. Churakova, M. Travis, E. Vaisberg, et al. 2002. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 16: 779-790.
25. Portielje, J. E., J. W. Gratama, H. H. van Ojik, G. Stoter, and W. H. Kruit. 2003. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol. Immunother. 52: 133-144.
26. Hemenway, C. S., and J. Heitman. 1999. Calcineurin. Structure, function, and inhibition. Cell Biochem. Biophys. 30: 115-151.
27. Yamashita, Y. I., M. Shimada, H. Hasegawa, R. Minagawa, T. Rikimaru, T. Hamatsu, S. Tanaka, K. Shirabe, J. I. Miyazaki, and K. Sugimachi. 2001. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res. 61: 1005-1012.
28. Yamashita, Y., M. Shimada, R. Minagawa, E. Tsujita, N. Harimoto, S. Tanaka, K. Shirabe, J. Miyazaki, and Y. Maehara. 2004. Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation. Mol. Cancer Ther. 3: 1177-1182.
29. Ramos, H. C., J. Reyes, K. Abu-Elmagd, A. Zeevi, N. Reinsmoen, A. Tzakis, A. J. Demetris, J. J. Fung, B. Flynn, J. McMichael, et al. 1995. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 59: 212-217.
30. Kamath, A. T., J. Pooley, M. A. O'Keeffe, D. Vremec, Y. Zhan, A. M. Lew, A. D'Amico, L. Wu, D. F. Tough, and K. Shortman. 2000. The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J. Immunol. 165: 6762-6770.
31. Iwai, T., Y. Tomita, S. Okano, I. Shimizu, Y. Yasunami, T. Kajiwara, Y. Yoshikai, M. Taniguchi, K. Nomoto, and H. Yasui. 2006. Regulatory roles of NKT cells in the induction and maintenance of cyclophosphamide-induced tolerance. J. Immunol. 177: 8400-8409.
32. Mayumi, H., K. Nomoto, and R. A. Good. 1988. A surgical technique for experimental free skin grafting in mice. Jpn. J. Surg. 18: 548-557.
33. Inamura, N., K. Nakahara, T. Kino, T. Goto, H. Aoki, I. Yamaguchi, M. Kohsaka, and T. Ochiai. 1988. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. Transplantation 45: 206-209. (Pubitemid 18084638)
34. Wada, H., M. Monden, M. Gotoh, H. Nakano, Y. Kita, and T. Mori. 1991. An attempt to induce tolerance to skin grafts in congenic mice with FK 506. Transplant. Proc. 23: 3280-3281.
35. Gardner, C. R. 1995. The pharmacology of immunosuppressant drugs in skin transplant rejection in mice and other rodents. Gen. Pharmacol. 26: 245-271.
36. Li, Y., X. C. Li, X. X. Zheng, A. D. Wells, L. A. Turka, and T. B. Strom. 1999. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5: 1298-1302.
37. Qin, Z., J. Schwartzkopff, F. Pradera, T. Kammertoens, B. Seliger, H. Pircher, and T. Blankenstein. 2003. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 63: 4095-4100.
38. Romero, P., J. C. Cerottini, and D. E. Speiser. 2004. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol. Immunother. 53: 249-255.
39. Zhou, Y., M. L. Bosch, and M. L. Salgaller. 2002. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J. Immunother. 25: 289-303.
40. Roychowdhury, S., K. F. May, Jr., K. S. Tzou, T. Lin, D. Bhatt, A. G. Freud, M. Guimond, A. K. Ferketich, Y. Liu, and M. A. Caligiuri. 2004. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res. 64: 8062-8067.
41. Marzo, A. L., B. F. Kinnear, R. A. Lake, J. J. Frelinger, E. J. Collins, B. W. Robinson, and B. Scott. 2000. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol. 165: 6047-6055.
42. Soejima, Y., A. Taketomi, T. Yoshizumi, H. Uchiyama, S. Aishima, T. Terashi, M. Shimada, and Y. Maehara. 2007. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation 83: 893-899.
43. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2: 52-58.
44. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4: 328-332.
45. Nestle, F. O., A. Farkas, and C. Conrad. 2005. Dendritic-cell-based therapeutic vaccination against cancer. Curr. Opin. Immunol. 17: 163-169.
46. Pardoll, D., and J. Allison. 2004. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat. Med. 10: 887-892.
47. Rabinovich, G. A., D. Gabrilovich, and E. M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267-296.
48. Serafini, P., C. De Santo, I. Marigo, S. Cingarlini, L. Dolcetti, G. Gallina, P. Zanovello, and V. Bronte. 2004. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53: 64-72.
49. Salvadori, S., G. Martinelli, and K. Zier. 2000. Resection of solid tumors reverses T cell defects and restores protective immunity. J. Immunol. 164: 2214-2220. (Pubitemid 30108782)
50. Moretta, L., G. Ferlazzo, C. Bottino, M. Vitale, D. Pende, M. C. Mingari, and A. Moretta. 2006. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol. Rev. 214: 219-228.
51. Tatsumi, T., T. Takehara, T. Kanto, T. Miyagi, N. Kuzushita, Y. Sugimoto, M. Jinushi, A. Kasahara, Y. Sasaki, M. Hori, and N. Hayashi. 2001. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res. 61: 7563-7567.
52. Martín-Fontecha, A., L. L. Thomsen, S. Brett, C. Gerard, M. Lipp, A. Lanzavecchia, and F. Sallusto. 2004. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. 5: 1260-1265.
53. Cohen, P. A., L. Peng, G. E. Plautz, J. A. Kim, D. E. Weng, and S. Shu. 2000. CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit. Rev. Immunol. 20: 17-56.
54. Strauss, G., W. Osen, and K. M. Debatin. 2002. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin. Exp. Immunol. 128: 255-266.
55. Eisele, R. M., P. Neuhaus, and G. Schumacher. 2008. Radiofrequency ablation of liver tumors using a novel bipolar device. J. Laparoendosc. Adv. Surg. Tech. A 18: 857-863.
56. Mazzolini, G., C. Qian, X. Xie, Y. Sun, J. J. Lasarte, M. Drozdzik, and J. Prieto. 1999. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther. 6: 514-522.
57. Mazzolini, G., J. Prieto, and I. Melero. 2003. Gene therapy of cancer with interleukin-12. Curr. Pharm. Des. 9: 1981-1991.
58. Schultz, J., L. Heinzerling, J. Pavlovic, and K. Moelling. 2000. Induction of long-lasting cytokine effect by injection of IL-12 encoding plasmid DNA. Cancer Gene Ther. 7: 1557-1565. (Pubitemid 32098766)
59. Jinushi, M., and H. Tahara. 2009. Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci. 100: 1389-1396.
60. Tirapu, I., M. Rodriguez-Calvillo, C. Qian, M. Duarte, C. Smerdou, B. Palencia, G. Mazzolini, J. Prieto, and I. Melero. 2002. Cytokine gene transfer into dendritic cells for cancer treatment. Curr. Gene Ther. 2: 79-89.
61. Melero, I., M. Duarte, J. Ruiz, B. Sangro, J. Galofré, G. Mazzolini, M. Bustos, C. Qian, and J. Prieto. 1999. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther. 6: 1779-1784.
62. Nishioka, Y., M. Hirao, P. D. Robbins, M. T. Lotze, and H. Tahara. 1999. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 59: 4035-4041.
63. Furumoto, K., S. Arii, S. Yamasaki, M. Mizumoto, A. Mori, N. Inoue, N. Isobe, and M. Imamura. 2000. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses. Int. J. Cancer 87: 665-672.
64. Tatsumi, T., T. Takehara, S. Yamaguchi, A. Sasakawa, T. Miyagi, M. Jinushi, R. Sakamori, K. Kohga, A. Uemura, K. Ohkawa, et al. 2007. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity. Gene Ther. 14: 863-871.
65. Bontkes, H. J., D. Kramer, J. J. Ruizendaal, E. W. Kueter, V. F. van Tendeloo, C. J. Meijer, and E. Hooijberg. 2007. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther. 14: 366-375.
66. He, X. Z., L. Wang, and Y. Y. Zhang. 2008. An effective vaccine against colon cancer in mice: use of recombinant adenovirus interleukin-12 transduced dendritic cells. World J. Gastroenterol. 14: 532-540.
67. Rodríguez-Calvillo, M., M. Duarte, I. Tirapu, P. Berraondo, G. Mazzolini, C. Qian, J. Prieto, and I. Melero. 2002. Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12. Exp. Hematol. 30: 195-204.
68. Miller, G., S. Lahrs, and R. P. Dematteo. 2003. Overexpression of interleukin-12 enables dendritic cells to activate NK cells and confer systemic antitumor immunity. FASEB J. 17: 728-730.
69. Ahuja, S. S., S. Mummidi, H. L. Malech, and S. K. Ahuja. 1998. Human dendritic cell (DC)-based anti-infective therapy: engineering DCs to secrete functional IFN-gamma and IL-12. J. Immunol. 161: 868-876.
70. Mazzolini, G., C. Alfaro, B. Sangro, E. Feijoó, J. Ruiz, A. Benito, I. Tirapu, A. Arina, J. Sola, M. Herraiz, et al. 2005. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J. Clin. Oncol. 23: 999-1010.
71. Sangro, B., G. Mazzolini, J. Ruiz, M. Herraiz, J. Quiroga, I. Herrero, A. Benito, J. Larrache, J. Pueyo, J. C. Subtil, et al. 2004. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J. Clin. Oncol. 22: 1389-1397.